|
| 固力康联合娃鱼降钙素治疗老年性骨质疏松的临床疗 效及安全性 |
| The efficacy and safety of Menatetrenone Soft Capsules combined with Salmon calcitonin in the treatment of elderly osteoporosis |
| |
| DOI：10.3969/j.issn.1006-7108.2017.05.018 |
| 中文关键词: 固力康 鲑鱼降钙素；骨质疏松症；临床疗效 |
| 英文关键词:Menatetrenone Soft Capsules Salmon calcitonin Osteoporosis Clinical effect |
| 基金项目: |
|
| 摘要点击次数: 925 |
| 全文下载次数: 555 |
| 中文摘要: |
| 目的 对固力康联合鲑鱼降钙素治疗老年性骨质疏松的临床疗效及安全性进行分析。方法 选取2014年9月至 2016年1月于我院治疗的122例老年性骨质疏松患者进行研究，按照患者入院时间进行分成两组，治疗组、对照组分别61 例，给予对照组患者鲑鱼降钙素进行治疗，治疗组患者给予固力康联合鲑鱼降钙素进行治疗，在治疗6月后，将两组患者的疼 痛VAS评分、腰椎及髋部骨密度、骨钙素（BGP)和β-胶原降解产物（β-CrossLaps)变化情况进行对比，同时对患者服药后的不 良反应发生率进行比较。结果 治疗6个月后两组患者VAS评分均较治疗前有明显改善（P<0.05),且治疗组患者评分明显 低于对照组（P <0.05)。治疗6个月后，两组患者骨密度较治疗前都显著改善（P<0.05),血清BGP和β-CrossLaps较治疗前有显著改变（P <0.05),且均明显优于对照组（P <0.05)。两组药品不良反应发生率比较，差异无统计学意义（P> 0.05)。结 论 固力康联合鲑鱼降钙素治疗老年性骨质疏松效果显著，安全性较高，值得在临床中推广应用。 |
| 英文摘要: |
| Objective To examine the clinical efficacy and safety of Menatetrenone Soft Capsules combined with Salmon calcitonin in the treatment of elderly osteoporosis. Methods The study was conducted in 122 cases of senile osteoporosis who were selected from patients attending clinics of our hospital from September 2014 to January 2016. Patients were grouped according to hospitalization time, with 61 patients in each group. Patients in the control group were given Salmon calcitonin, and patients in the treatment group received combined Menatetrenone Soft Capsules and Salmon calcitonin treatment. After 6 months of treatment, comparisons were made between the two groups on the changes in pain VAS score, bone mineral density, Osteocalcin (BGP) and beta-collagen degradation products (β-CrossLaps) , and the incidence of adverse reactions. Results The VAS scores of patients in both groups 6 months after the treatment were all improved compared with before treatment (P <0. 05) , and the scores of patients in the treatment group were significantly lower than those in the control group (P < 0. 05). After 6 months of treatment, BMD of both groups significantly improved (P <0. 05). Serum BGP and β-CrossLaps changed significantly compared with before treatment (P < 0. 05 ) , and all index were better than those of the control group ( P < 0. 05 ). When comparing the incidence of adverse drug reaction between the two groups, the difference had no statistical significance ( P >0.05). Conclusion The combination of Menatetrenone Soft Capsules with Salmon calcitonin in the treatment of elderly osteoporosis is effective and safe, and suitable for wider clinical application. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |